Abbott Laboratories

NYSE:ABT

Medical - Devices

Healthcare
$104.48 -0.58%

-$0.51 today

Market cap
$180.95B
Beta
0.62
P/E (TTM)
24.5
EPS (TTM)
$3.59
Dividend yield
2.77%
52W Low $81.97High $139.06

Volume 7.02M

Average 13.17M

ABT Deferred Tax Liabilities

Taxes owed in future periods because of timing differences between accounting and tax rules.

Abbott LaboratoriesNYSE: ABT

Deferred Tax Liabilities · Q2 FY2026 · quarter ended Jun 2026

Deferred tax liabilities remains negative

Q2 FY2026 deferred tax liabilities was $0, compared with $0 a year earlier. Over 3 fiscal years it compounded at +2.0% a year.

Context

  • Deferred tax liabilities amounted to 0.0% of total assets at the end of Q2 FY2026, unchanged from a year earlier.
  • Deferred tax liabilities increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$1.96B+42.6% YoY
Year agoJun 2025
$0— since
Deferred Tax Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+42.6%——
3-year CAGR+2.0%——
5-year CAGR——
10-year CAGR——

Deferred Tax Liabilities history

USD · from the balance sheet

Latest · FY2025
1.96B USD
Year-over-year change
+42.6%
4-year CAGR
-1.4%

Deferred Tax Liabilities vs competitors

How ABT compares with its peers on the latest reported figures

  • ABT's Jun 2026 deferred tax liabilities of $0 is the 6th highest of the 10 companies compared; the peer median is $221M.
  • Deferred tax liabilities amounts to 0.0% of total assets for ABT, versus a peer median of 0.4%.
ABT Competitors Peer median
Deferred Tax Liabilities for ABT and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
JNJJohnson & JohnsonSep 2026$4.84B -19.3%+19.4%2.4%
BDXBecton, Dickinson and CompanySep 2026$2.2B —-3.5%4.3%
MDTMedtronic plcJul 2026$349M -16.1%-20.0%0.4%
GEHCGE HealthCare Technologies Inc.Jun 2026$315M +82.1%-19.5%0.8%
BSXBoston Scientific CorporationJun 2026$221M -2.2%+15.2%0.5%
ABTAbbott LaboratoriesJun 2026$0 —+2.0%0.0%
TMOThermo Fisher Scientific Inc.Sep 2026$0 -100.0%-19.4%0.0%
DHRDanaher CorporationSep 2026$0 ——0.0%
SYKStryker CorporationJun 2026$0 —+26.9%0.0%
EWEdwards Lifesciences CorporationJun 2026$0 ——0.0%
Peer median (excluding ABT) $221M-16.1%-3.5%0.4%

Competitors are the stored peer set for ABT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents9.8B9.88B6.9B7.62B8.52B
Short-term Investments450M288M383M351M417M
Net Receivables6.49B6.22B6.57B6.93B7.93B
Inventory5.16B6.17B6.57B6.19B6.49B
Other Current Assets2.35B2.66B2.26B2.57B2.64B
Total Current Assets24.24B25.22B22.67B23.66B26B
Property, Plant & Equipment (Net)10.11B10.28B11.28B11.73B12.94B
Goodwill23.23B22.8B23.68B23.11B24.04B
Intangible Assets12.74B10.45B8.82B6.65B5.53B
Long-term Investments903M766M799M886M918M
Tax Assets00000
Other Non-current Assets3.97B4.92B5.98B15.38B17.3B
Total Non-current Assets50.96B49.21B50.54B57.76B60.72B
Total Assets75.2B74.44B73.21B81.41B86.71B
Account Payables4.41B4.61B4.3B4.2B4.24B
Short-term Debt999M2.48B1.33B1.75B3.31B
Tax Payables306M343M492M594M569M
Deferred Revenue00000
Other Current Liabilities5.77B6.5B6.13B5.91B5.54B
Total Current Liabilities13.11B15.49B13.84B14.16B16.5B
Long-term Debt17.3B14.52B13.6B12.63B10.83B
Deferred Tax Liabilities2.07B1.84B1.22B1.37B1.96B
Deferred Revenue (Non-current)00000
Other Non-current Liabilities5.74B4.74B4.78B4.46B3.73B
Total Non-current Liabilities26.07B22.04B20.55B19.36B17.45B
Total Liabilities39.17B37.53B34.39B33.51B33.94B
Common Stock24.47B24.71B24.87B25.15B25.53B
Retained Earnings31.53B35.26B37.55B47.26B49.78B
Accumulated OCI(8.37B)(8.05B)(7.84B)(7.91B)(6B)
Other Stockholders Equity00000
Minority Interest222M219M224M237M641M
Total Equity36.02B36.91B38.83B47.9B52.77B
Total Debt19.25B17.95B15.87B15.28B15.07B
Net Debt9.45B8.06B8.98B7.66B6.55B

Abbott Laboratories

NYSE:ABT

Intrinsic Alpha fair value

Locked

Current Price

$104.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.